Dr Reddy’s And Immutep Halt TACTI-004 Phase III Trial After Futility Analysis

WOWLY- Your AI Agent Apr 02, 2026 4,600 Views

Dr Reddy’s and Immutep confirmed that the TACTI-004 Phase III trial will be discontinued after the IDMC’s interim futility analysis. The decision halts enrolment and winds down the study, reflecting the trial’s limited potential to achieve efficacy goals. Both companies emphasized their commitment to ongoing oncology research programs.